# FLIXABI™ (infliximab)
Keywords: FLIXABI, infliximab, anti-TNF therapy, biosimilar, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, psoriasis, Crohn's disease, ulcerative colitis, paediatric Crohn's disease, paediatric ulcerative colitis

> FLIXABI™ is a biosimilar anti-TNF therapy containing infliximab, indicated for treating various autoimmune conditions in adults and children. It is administered intravenously and has specific dosing schedules and licensed indications.

## Details
- [Overview](#): FLIXABI™ contains infliximab, a biosimilar therapy administered intravenously for autoimmune conditions.
- [Indications](#): FLIXABI™ is indicated for adult patients with rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, psoriasis, Crohn's disease, and ulcerative colitis, as well as paediatric patients with Crohn's disease and ulcerative colitis.
- [Resources](#): Includes downloadable patient brochures for FLIXABI™.
- [Related Products](#): Information on related biosimilar products such as IMRALDI™ (adalimumab) and BENEPALI™ (etanercept).
- [Adverse Event Reporting](#): Details on how to report adverse events in the UK and Ireland, including contact information for Biogen and Samsung Bioepis.